Stay updated with breaking news from Clinical Development Program. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
Chemomab Therapeutics Announces Fourth Quarter and Year End 2021 Financial Results and Provides a Corporate Update - read this article along with other careers information, tips and advice on BioSpace
“Noxopharm is a unique company. I feel very honoured to be chosen as its next CEO and I am excited to lead the company through its next...
“Noxopharm is a unique company. I feel very honoured to be chosen as its next CEO and I am excited to lead the company through its next...
Daiichi Sankyo Company, Limited (hereafter, Daiichi Sankyo) today announced that the first patient was dosed in the global DESTINY-Lung04 phase 3 trial evaluating the efficacy and safety of ENHERTU (trastuzumab
DESTINY-Breast03 data presented at SABCS 2021 showed Daiichi Sankyo and AstraZeneca's ENHERTU demonstrated a similar benefit in patient subgroups, including those with stable brain metastases, compared